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Abstract
Methods employed in genome-wide association studies are not feasible ways to explore genotype–phenotype associations in
rare disorders due to limited statistical power. An alternative approach is to examine relationships among specific single
nucleotide polymorphisms (SNPs), selected a priori, and behavioural characteristics. Here, we adopt this strategy to examine
relationships between three SNPs (5-HTTLPR, MAOA, COMT) and specific clinically-relevant behaviours that are
phenotypic of fragile X syndrome (FXS) but vary in severity and frequency across individuals. Sixty-four males with FXS
participated in the current study. Data from standardised informant measures of challenging behaviour (defined as physical
aggression, property destruction, stereotyped behaviour, and self-injury), autism symptomatology, attention-deficit-
hyperactivity-disorder characteristics, repetitive behaviour and mood/interest and pleasure were compared between each
SNP genotype. No association was observed between behavioural characteristics and either 5-HTTLPR (serotonin) or
MAOA (monoamine oxidase) genotypes. However, compared to the COMT (dopamine) AG and GG genotypes, the AA
genotype was associated with greater interest and pleasure in the environment, and with reduced risk for property
destruction, stereotyped behaviour and compulsive behaviour. The results suggest that common genetic variation in the
COMT genotype affecting dopamine levels in the brain may contribute to the variability of challenging and repetitive
behaviours and interest and pleasure in this population. This study identifies a role for additional genetic risk in
understanding the neural and genetic mechanisms contributing to phenotypic variability in neurodevelopmental disorders,
and highlights the merit of investigating SNPs that are selected a priori on a theoretical basis in rare populations.
Introduction
With recent advances in genotyping technologies, the study
of genotype–phenotype relationships has received sig-
nificant attention in both the general population and the field
of neurodevelopmental and psychiatric disorders. The
extant research has employed a variety of methods,
including detailed behavioural phenotyping of individuals
with single and multiple gene disorders, genome wide
association studies (GWAS) and examining phenotypic
differences related to individual differences in single
nucleotide polymorphism (SNP) genotypes. These lines of
research have each identified putative relationships between
genetic factors and various aspects of cognitive, social,
emotional and behavioural functioning [1–3].
Empirical research delineating behavioural phenotypes
has uncovered strong evidence for features that are char-
acteristic of different genetic disorders. For example,
syndrome-specific patterns include almost universal levels
of self-injurious behaviour in Lesch–Nyhan syndrome, a
threefold increase in aggression in individuals with
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Angelman syndrome, and elevated stereotyped behaviour in
Rubinstein–Taybi syndrome [2]. Despite the well-defined
behavioural phenotypes associated with genetic syndromes,
there is individual within-disorder variability in the pre-
sence, severity and frequency of some behaviours. For
example, autism symptomatology is heightened in indivi-
duals with fragile X syndrome (FXS) and, although traits of
autism have been reported in ~75% of individuals with FXS
[4], only 30% display these traits at the severity required to
meet cut-off for an autism spectrum disorder (ASD) [5]. The
factors that protect some individuals and place others with
the same monogenic disorder at risk are currently unknown.
Identifying additional genetic risk for these and other
behavioural characteristics may further understanding of the
mechanisms contributing to phenotypic variability within
these populations. However, statistical modelling has indi-
cated that GWAS studies should utilise sample sizes
between several thousands to more than tens of thousands to
effectively answer simple questions, and in the range of
50,000–100,000 or larger to answer more complex ques-
tions [6]. The required sample sizes for GWAS would,
therefore, be impossible to achieve in studies of individual
rare diseases and disorders.
An alternative approach to GWAS in uncovering
genotype–phenotype relationships, which offers the oppor-
tunity to capture individual variability in behavioural
characteristics, is through examining relationships among
specific SNPs and behavioural characteristics. Here, SNPs
are selected a priori, on a theoretical basis with regard to
their functions and previous findings, as evidence suggests
many SNPs directly or indirectly affect neurotransmitter
function and other neural mechanisms that may play a
particular role in phenotypic expression. Our work, and that
of others, has identified that normal genotypic variation is
associated with differences in important behaviours in
typically developing populations [7, 8].
SNP genotype–phenotype research has recently been
extended to examine how common variation in SNP gen-
otypes impact behaviour within the context of genetically-
mediated syndromes. For example, Hessl et al. [9] reported
an association between variation of serotonin-related 5-
HTTLPR genotype and aggressive and stereotyped beha-
viour in FXS. Another study uncovered an association
between this SNP genotype and improvements in clinical
measures when children with FXS received medication
versus a placebo [10]. Studies of SNP genotype–phenotype
relationships have also been subject to some degree of non-
replication, likely due to variations in study design, different
populations and different definitions of phenotypes [11]. In
the field of neurodevelopmental disorders, where popula-
tions and phenotypic characteristics are often defined at a
fine-grained level and samples are less readily available,
there have been limited attempts at replication.
Fragile X syndrome as a model to investigate
polymorphism-behaviour relationships
Affecting ~1 in 4000 males and 1 in 8000 females, FXS is
the most common cause of inherited intellectual disability
[12]. It is caused by an expansion of cytosine–guanine–
guanine repeats on the FMR1 gene. FXS is associated with
a number of clinically significant behaviours, including self-
injury and aggressive behaviour, ASD symptomatology,
hyperactivity and impulsivity, and social anxiety [13].
Despite comparatively heightened prevalence rates in FXS,
the nature and severity of these behaviours varies across
individuals. The role of secondary genes, namely those
associated with the serotonin-transporter-linked poly-
morphic region (5-HTTLPR) and Monoamine oxidase A
(MAOA), has been investigated to further explain the
variability of aggressive, self-injurious and stereotypic
behaviours in FXS [9]. This previous study reported an
association between the L genotype of 5-HTTLPR and
aggressive and stereotyped behaviour, but no association
between these behaviours and MAOA.
Interestingly, the relationship between 5-HTTLPR and
aggressive behaviour reported in this previous study is
divergent with that reported in the general population. The
present study aims to replicate these findings, and expand
on them by exploring the role of 5-HTTLPR and MAOA
genotypes for a wider range of behavioural characteristics,
which are variably associated with the behavioural pheno-
type of FXS. This includes challenging behaviour (defined
here as physical aggression, property destruction, stereo-
typed behaviour and self-injury), ASD characteristics,
attention-deficit-hyperactivity-disorder (ADHD) character-
istics, repetitive behaviour and mood/interest and pleasure.
In addition, the present study will delineate the role of the
dopamine-related SNP, COMTVal158Met, in these beha-
vioural characteristics, which has not yet been explored in
FXS but has been associated with behaviour in other
populations. See Supplementary information File 1 for
additional information on 5-HTTLPR, MAOA and COMT
including background and existing literature. Relationships
between each of these three SNPs in the expression of
clinically relevant behaviours, including those measured
here, are reported in different populations. However, most
of these relationships have been not been replicated, likely
due to differences in definitions of phenotypes and mea-
sures used to capture phenotypic data, as well as insuffi-
ciently powered studies, and variability in study samples.
Interestingly, the possibility of the same candidate gene or
DNA variant being associated with different risks in dif-
ferent populations has been highlighted [11].
To our knowledge, only one study has investigated the role
of variation in SNP genotypes to phenotypic variation in FXS
[9]. Based on this, it was hypothesised that the L genotype of
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5-HTTLPR will be associated with aggressive and stereo-
typed behaviour whilst no association between challenging
behaviour and MAOA will be found. The role of 5-HTTLPR
and MAOA in other behavioural characteristics (autism
symptomatology, ADHD characteristics, repetitive behaviour
and mood disorders) has not been investigated in FXS.
Therefore, secondary hypotheses for these additional beha-
viours were based on research conducted in other populations.
Such research indicates that: (a) the 5-HTTLPR S allele will
be associated with ADHD characteristics and mood/interest
and pleasure, whereas the L allele will be associated with
repetitive behaviour, (b) the 4-repeat MAOA allele will be
associated with ASD, (c) the AA COMT genotype will be
associated with challenging behaviour, ADHD characteristics
and mood/interest and pleasure whereas the GG genotype
would be associated with repetitive behaviour. No hypotheses
were generated for additional polymorphism–behaviour rela-
tionships due to a lack of literature and/or mixed results.
Methods
Participants
This study was conducted as part of a large-scale ques-
tionnaire study investigating behaviour in individuals with a
range of different neurodevelopmental disorders. Parents and
carers of males with FXS were recruited to the questionnaire
study through the Fragile X Society, the UK family support
group. Overall, parents or carers of 252 males with FXS
returned an eligible questionnaire pack. For the current study,
each of these families were contacted directly and asked if
they would be willing to provide a saliva sample from their
child or the person they care for. One hundred and two
families agreed to take part in this phase of the project. Tel-
ephone contact was attempted with all 102 families that
initially agreed to take part. Fourteen families were unable to
collect saliva due to behavioural challenges. Saliva samples
were returned from 64 males with FXS (62.75%). The
remaining families were either not contactable or they verb-
ally agreed to return saliva samples but these were not
received. A diagnosis of FXS was confirmed through genetic
testing for all participants. The demographic characteristics of
the participants are displayed in Table 1.
Measures
Each participant’s primary caregiver completed a demo-
graphic questionnaire, the Wessex Scale, the Challenging
Behaviour Questionnaire (CBQ), the Social Communica-
tion Questionnaire (SCQ), the Activity Questionnaire
(TAQ), the Repetitive Behaviour Questionnaire (RBQ) and
the Mood, Interest and Pleasure Questionnaire-Short Form
(MIPQ-S). See Supplementary information File 2 for
additional information on the questionnaire measures.
Procedure
Parents and carers of males with FXS that agreed to take
part in the study were sent an Oragene DNA (OG-575)
saliva self-collection kit with accompanying instructions on
using the device and packaging the sample for postal return.
Families that provided saliva samples were contacted to
request retrospective information on the participant’s
medication use.
Genetic analysis
Saliva samples were analysed to confirm a diagnosis of FXS,
as well as to identify the 5-HTTLPR (S/S, S/L, L/L), MAOA
(number of repeats) and COMT (AA, AG, GG) genotypes.
DNA was extracted from saliva samples using PrepIT L2
protocol from DNA Genotek ON, Canada according to the
manufacturer’s instructions. Fragile X analysis was performed
using primers described in Hantash et al. [14]. The PCR was
performed using Fast Start polymerase (Roche) under the
following conditions: 2× Buffer, 90 mM MgCl, 20% Q-
solution (Qiagen), 1% Deaza dGTP (NEB), 10% DMSO, 25
mM each primer, 1U Taq with 20 ng DNA. Cycling
Table 1 Participant characteristics for the full sample.
Participant characteristic (n= 64)
Chronological age mean (SD)a 18.11 (9.67)
Range 3.93–41.24
% Verbal (speak/sign more than 30 words)a 89.1
% Mobile (walk unaided)a 96.9
% Partly able/ableb 89.1
% Meeting cut off for ASDc 70.3
% Meeting cut off for autismc 31.3
% displaying self-injurious behaviour within last
monthd
43.8
% displaying physical aggression within last monthd,e 40.6
% displaying destruction of property within last
monthd,f
34.4
% displaying stereotyped behaviour within last monthd 60.9
aChronological age, verbal and mobility data obtained from the
Demographic Questionnaire. Age data missing from one participant.
bAbility measured by the self-help subscale of the Wessex Scale.
cASD and autism cut off data obtained from the Social Communication
Questionnaire (SCQ). SCQ data are not available for six participants.
dData on challenging behaviour including self-injurious behaviour,
physical aggression, destruction of property and stereotyped behaviour
obtained from the Challenging Behaviour Questionnaire.
ePhysical aggression data not available for two participants.
fDestruction of property data not available for one participant.
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conditions were as follows (with the ramp speed adjusted to
2°/s) 95 °C 15min, followed by 2 cycles of 95 °C 30 s, 65 °C
30 s 72 °C, then a 2° decrease in annealing temp every 2
cycles plus an increase in cycle number for the next eight
rounds, followed by a final extension of 10min 72 °C. Ana-
lysis of the fragments was performed using an ABI
3730 sequencer and analysed using Genemapper software 5
and Rox500 size standard (Applied Biosystems).
COMT analysis was performed using TaqMan genotyping
(assay ID C__25746809_50) according to the manufacturer’s
instructions. 5HTTLPR analysis was performed as described
in Wray et al. [15]. MAOA analysis was performed using
primers described in Guo et al. [16]. The PCR was performed
using Fast Start polymerase (Roche) under the following
conditions: 2x Buffer, 90mM MgCl, 20% Q-solution (Qia-
gen), 1% Deaza dGTP (NEB), 10% DMSO, 25mM each
primer, 1U Taq with 20 ng DNA. Cycling conditions were as
follows: 95 °C 10min, followed by 2 cycles of 95 °C 30 s, 65
°C 30 s 72 °C 1min, then a 2° decrease in annealing temp
every 2 cycles plus an increase in cycle number for the next
seven rounds, with a final amplification on 25 cycles of 95 °C
30 s, 56 °C 30 s and 72 °C 1min. Analysis of the fragments
was performed using an ABI 3730 sequencer and analysed
using Genemapper software 5 software and Rox500 size
standard (Applied Biosystems).
Data analysis
There were five sibling pairs in the participant sample (four
twin pairs). For reporting the prevalence of different gen-
otypes in the same, one sibling from each pair was ran-
domly removed to avoid reporting bias. However, data from
all 64 participants were included in the genotype-phenotype
analyses based on the assumption that the behavioural
phenotype and, therefore, the genotype-phenotype rela-
tionship is unlikely to be identical between siblings.
The distribution of questionnaire data was inspected for
normality via the One-Sample Kolmogorov–Smirnov test.
Data from the following subscales and total scores were
normally distributed (p > 0.05): TAQ Total Score, MIPQ-S
Interest and Pleasure subscale, RBQ Repetitive Language
subscale, RBQ Total Score, SCQ Total Score. Data from all
other subscales and total scores were not normally dis-
tributed (p < 0.05).
For genotype-phenotype analyses, one-way ANOVAs
and Kruskal-Wallis tests were conducted to assess differ-
ences between the different 5-HTTLPR and COMT geno-
types at full scale and subscale level of each questionnaire
measure that yields continuous data (CBQ self-injury
severity, SCQ, TAQ, RBQ, MIPQ). Where differences
existed, independent samples t-tests and Mann–Whitney
tests were conducted to locate the source of difference. The
majority of participants expressed either 3 or 4 MAOA
repeats. Independent samples t-tests and Mann–Whitney
tests were conducted to assess differences between those
with three repeats and those with four repeats at full scale
and subscale level of each questionnaire measure yielding
continuous data. Chi-square tests were used to analyse
differences between 5-HTTLPR, COMT, and MAOA
genotypes and categorical items on the CBQ (presence of
self-injury, destruction of property, physical aggression and
stereotyped behaviour).
The sample size reported here is the largest for studies of
SNPs in FXS, and is similar to or larger than the sample size
for existing published studies of other neurodevelopmental
disorders including autism (n= 73 [17]; n= 41 [18]). A
post-hoc power analysis was performed for power estima-
tion given the available sample size. Assuming a medium
effect size of 0.5, and a p value of 0.05, power was deter-
mined to be 0.95 for ANOVAs with three participant groups
(5-HTTLPR and COMT analyses) and 0.41 for two groups
(MAOA analysis).
Results
Kruskal–Wallis and Mann–Whitney tests revealed that
neither chronological age nor ability level, as measured by
the Wessex, was associated with either the 5-HTTLPR,
MAOA or COMT genotypes (all p > 0.05). Table 2 presents
the mean subscale and full-scale scores for each measure as
a function of 5-HTTLPR, MAOA and COMT genotypes.
5-HTTLPR
Excluding one from each sibling pair (total n= 59), 5-
HTTLPR genotyping revealed 18 participants homozygous
for the L/L genotype (30.51%), 18 participants homozygous
for the S/S genotype (30.51%) and 23 participants with the
L/S genotype (38.98%).
Including all participants (n= 64), no significant differ-
ences were revealed between the three genotype groups on
the questionnaire measures at subscale level (all p > 0.05).
In addition, no significant differences were revealed on
categorical items of the CBQ assessing the presence of self-
injury, destruction of property, aggression and stereotyped
behaviour (all p > 0.05). Power estimation for this analysis
was high (0.95) and significant effects of 5-HTTLPR and
challenging behaviour have previously been reported in a
smaller sample size of 47 males with FXS [9]. Therefore,
statistical power is not thought to underlie the null results.
MAOA
Excluding one from each sibling pair (total n= 59), MAOA
genotyping revealed 19 participants with 3 repeats
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(32.20%), 37 participants with 4 repeats (62.71%), two
participants had 3.5 repeats (3.39%), and one participant
had 5 repeats (1.69%). Due to the small numbers of parti-
cipants expressing 3.5 and 5 MAOA repeats, the
genotype–phenotype analysis included comparisons only
between those with three and those with four repeats.
Including all eligible data (n= 61), no significant dif-
ferences were revealed between these two genotype groups
on the questionnaire measures at subscale level (all p >
0.05). In addition, no significant differences were revealed
on the categorical items assessing the presence of any form
of challenging behaviour (all p > 0.05). Power estimation
for these analyses was low and so caution should be applied
when interpreting these results.
COMT
COMT genotype information could not be obtained for one
participant. Excluding one from each sibling pair (total n=
58), COMT genotyping revealed nine participants homo-
zygous for the A/A genotype (15.52%), 11 homozygous for
the G/G genotype (18.97%) and 38 with the A/G genotype
(65.52%).
Chi-square tests including all participants (n= 63),
revealed a significant difference between the COMT gen-
otypes on the presence of destruction of property (χ2(2)=
8.293, p= 0.016) and stereotyped behaviours measured by
the CBQ (χ2(2)= 6.850, p= 0.033; Fig. 1). Follow-up
analyses revealed that this significant difference was driven
by lower scores, and therefore lower levels of property
destruction and stereotyped behaviour, in those with the
AA versus both the AG genotype (destruction of property:
χ2(1)= 8.033, p= 0.005; stereotyped behaviour: χ2(1)=
6.062, p= 0.014) and the GG genotype, although this dif-
ference was marginal for destruction of property (destruc-
tion of property: χ2(1)= 3.850, p= 0.050; stereotyped
behaviour: (χ2(1)= 4.545, p= 0.033).
Significant differences were also revealed between the
COMT genotypes and Stereotyped Behaviour (χ2(2)= 7.790,
p= 0.020) and Compulsive Behaviour (χ2(2)= 6.927, p=
0.031) subscales of the RBQ (Fig. 2). Individuals with the AA
genotype scored significantly lower than those with the AG
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and GG phenotypes on both the Stereotyped Behaviour
subscale (AA vs. AG: U= 126.500, p= 0.031; AA vs. GG:
U= 14.500, p= 0.006) and the Compulsive Behaviour sub-
scale (AA vs. AG: U= 115.000, p= 0.014; AA vs. GG: U=
22.000, p= 0.020). These results indicate that those with the
AA genotype display lower levels of stereotyped and com-
pulsive behaviour than those with the AG or GG genotypes.
Significant differences were also revealed between
COMT genotypes and the Interest and Pleasure subscale
(F (2, 62)= 4.338, p= 0.017) of the MIPQ-S (Fig. 3).
Specifically, those with the AA genotype scored sig-
nificantly higher, indicating higher interest and pleasure,
than those with the AG phenotype on the Interest and
Pleasure subscale (p= 0.015).
Medication
As medication may impact on the behaviours being assessed
in the current study, retrospective medication data were
obtained from 60 participants. All analyses were re-conducted
excluding data from 11 participants that took psychoactive
medication within six months of questionnaire completion.
The pattern of results remained largely unchanged. The only
distinctions were (1) differences between COMT genotypes
and the stereotyped behaviour subscale of the CBQ were no
longer significant (p > 0.05), (2) lower levels of insistence of
sameness in individuals with the AA COMT genotype com-
pared to those with the AG genotype (χ2(2) = 6.302, p=
0.043; AG versus AA: U= 61.000, p= 0.038), and (3) dif-
ferences between COMT genotypes and interest and pleasure
were no longer significant (p > 0.05).
Discussion
Here, we present examinations of putative genotype–
phenotype associations between three SNPs (5-HTTLPR,
MAOA and COMT), selected a priori, and a range of
clinically relevant behaviours in males with FXS to identify
additional genetic risk for these behavioural characteristics.
Males with FXS are at high risk of displaying each of the
behavioural characteristics investigated in the current
study, namely, challenging behaviour (defined here as
physical aggression, property destruction, stereotyped
behaviour, and self-injury), autism symptomatology,
ADHD characteristics, repetitive behaviour and low mood.
However, the frequency and severity of each of these
behavioural characteristics is variable within the FXS
population. Our results indicate that common genetic var-
iation in the dopamine-related COMT genotype contributes
meaningfully to clinical variability in challenging and
repetitive behaviours and interest and pleasure character-
istics in this population. Specifically, compared to the AG
and GG genotypes, the AA genotype was associated with
reduced risk for property destruction, stereotyped and
compulsive behaviour, and with greater interest and plea-
sure in the environment. No association was observed
between behavioural characteristics and either serotonin-
related (5-HTTLPR) or monoamine oxidase related
(MAOA) genotypes. The results of the current study con-
tribute to the emerging field on personalised treatments
and, if replicated, highlight that variation in COMT may
inform tailored interventions. Understanding the genetic
basis for variable behavioural expression across people
with FXS has implications for early detection of the
heightened risk for these and other clinically significant
behaviours, which can ultimately optimise outcomes for
these individuals through biologically informed and pre-
ventative interventions.
5-HTTLPR
The lack of association between the 5-HTTLPR genotype
and challenging behaviour is inconsistent with the one
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existing study investigating this relationship in males with
FXS [9]. This previous study reported that individuals with
the L/L genotype displayed significantly higher levels of
aggressive and destructive behaviour than those with the S/
S genotype, and higher levels of stereotypic behaviour than
those with the S/L genotype. A potential reason for this
discrepancy is differences in population characteristics.
Specifically, 75 and 98% of the sample reported in Hessl
et al. [9] demonstrated aggressive and stereotyped beha-
viour, respectively, within a two-month period. In contrast,
only 40 and 60% of the sample included in the current study
demonstrated aggressive and stereotyped behaviour,
respectively, within the previous month. Thus, the overall
severity of challenging behaviour was substantially higher
in the study sample reported by Hessl et al. [9] than in the
current sample. In addition, the measures used to capture
information on property destruction, self-injurious and
aggressive behaviour differed between the two studies. The
study by Hessl et al. [9] used a five-point frequency scale
and a four-point severity scale to assess self-injurious
behaviour, stereotyped behaviour, and aggression/destruc-
tion over the past two months. The current study focussed
on the presence of aggressive behaviour and property
destruction over the past one month, and the presence and
severity of self-injurious behaviour with the latter capturing
length of episode, restraint, and frequency on a five-point
scale. In the present study, stereotyped behaviour was
captured using two instruments, one assessing presence and
another assessing frequency on a five-point scale. All these
measurement differences may have also contributed to the
discrepant findings.
The association between the L/L genotype and aggres-
sive behaviour has also been reported in individuals with
ASD [17], but only when using a single parent-interview
item and not when this same behaviour was measured via
observation. The same relationship has also been reported in
individuals with intellectual disability who display aggres-
sive behaviour [19]. Again, the severity of aggressive
behaviour may be higher in individuals living in residential
homes than with their parents or primary caregivers, as was
the case with most participants in the current study.
Therefore, one possible explanation for the discrepancy
between the findings reported in the current study and those
of Hessl et al. is an interaction among FXS, 5-HTTLPR
genotypes and environments, which increase overall rates of
challenging behaviour in individuals with FXS. Future
studies should, therefore, include measures of participant
and environmental factors related to risks for challenging
behaviour. In addition, challenging behaviour encapsulates
a broad range of behaviours and, therefore, specificity of the
construct being measured is important in future studies of
genotype–phenotype associations [see 20].
The results reported here do not support existing research
conducted in the other populations indicating a relationship
between 5-HTTLPR and other behavioural characteristics
including ADHD [21–23], ASD symptom severity [17] and
depression [24, 25]. Many of these studies were conducted
in the general population, which highlights the importance
of conducting genotype–phenotype studies in unique, well-
defined populations, such as FXS.
MAOA
The current study revealed no significant differences in
behavioural characteristics between individuals with three
versus four MAOA repeats. This is consistent with pre-
vious findings by Hessl et al. [9]. However, limited sta-
tistical power may account for the results in both the
existing and current study. Research has generally reported
mixed results for MAOA genotypes and aggressive beha-
viour within the general population, particularly when a
direct association between genotype and phenotype is
investigated, as effects of MAOA appear more likely to be
mediated by environmental interactions [26, 27]. Contra-
dictory results have also been reported in neurodevelop-
mental disorders with one study reporting a twofold higher
risk of autism in individuals with four versus three MAOA
repeats [28], and another study reporting that the three
repeat allele was associated with increased severity of
autism [18]. Individuals with FXS show an atypical profile
of ASD-related impairments, which has previously
accounted for subtle differences in FXS and idiopathic
ASD populations [29], and may explain the lack of asso-
ciation reported here.
COMT
The results reported here revealed that the AA genotype of
COMT is associated with greater interest and pleasure, and
with reduced risk for property destruction, compulsive
behaviour and stereotyped behaviour. To our knowledge,
this is the first study to explore the relationship between
genotypes of this dopamine-related SNP and behavioural
characteristics in individuals with FXS, and indicates that
variation in genetically-mediated dopamine levels in the
brain may go some way toward explaining the variability in
the presence and severity of a number of behavioural
characteristics. Interestingly, the AA genotype has been
associated with increased depression in the general popu-
lation [30, 31], suggesting that the mechanisms contributing
to this genotype–phenotype relationship may be different in
those with and without FXS. Mixed results have been
reported in the general population with regard to other
behavioural characteristics and, therefore, the current study
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expands on this by highlighting a relationship between the
AA genotype and compulsive and stereotyped behaviour in
individuals with a well-defined genetic syndrome. The AA
genotype results in higher dopamine in the prefrontal cor-
tex. Importantly, the effect of these increases in dopami-
nergic function may be dependent on the level of pre-
existing dopamine in the system [32]. For example,
increased levels of dopamine, or larger doses of dopamine
administered as treatment in clinical populations such as
Parkinson’s Disease, have been linked to impulsivity and
compulsive behaviour [33, 34], whereas they decrease
impulsivity in individuals with ADHD [35]. These findings
point to a likely important relationship between dopami-
nergic function and compulsive behaviour, in which COMT
genotypes play a role. However, the exact mechanisms
linking COMT, dopaminergic function and compulsive
behaviour for individuals with neurodevelopmental dis-
orders requires further investigation.
There are several strengths to this investigation into the
role of three distinct SNPs on specific clinically relevant
behavioural characteristics, including the a priori selection
of SNPs based on existing theoretical bases. In addition, the
current study includes the largest FXS sample to date to
examine SNPs as a genetic basis for variability in the
behavioural phenotype. Finally, the current study used a
number of standardised measures, which have been
designed specifically for people with intellectual disability,
to assess a wide range of behavioural characteristics, cov-
ering challenging behaviour, autism symptomatology,
ADHD characteristics, repetitive behaviour, and mood/
interest and pleasure. A limitation of the current study is the
lack of IQ measures to characterise the ability level of
participants. However, this was a product of conducting a
postal survey in order to maximise the response rate for the
largest possible sample size, and the Wessex served as a
proxy for intellectual and adaptive functioning. In addition,
a number of statistical comparisons were employed to fully
investigate the role of 5-HTTLPR, MAOA and COMT
variation in behavioural characteristics. The number of
comparisons, as well as the modest sample size, particularly
in the COMT A/A group, increases the chance of Type 1
error. However, such issues are inevitable when collecting
data from individuals with rare genetic syndromes. Apply-
ing stringent statistical methods to counteract this may
eliminate the reporting of a true association. Here, measures
were not taken to account for multiple comparisons. Rather,
it is suggested that the results are interpreted with caution
and replication is encouraged. In addition, given the chal-
lenges associated with collecting saliva samples from indi-
viduals with FXS, especially those displaying self-injurious
or aggressive behaviour, the sample of this study, as well as
other studies utilising similar methodologies, may be biased
in such a way that excludes those with the most severe
presentations of these behaviours.
Conclusions
This is the first investigation of the differential association
between three SNPs, which affect brain functions, 5-
HTTLPR (serotonin), MAOA (monoamine oxidase) and
COMT (dopamine), and a wide range of clinically important
behavioural characteristics in individuals with FXS, a well-
defined genetically mediated syndrome associated with a
heightened risk of displaying such behaviours. This study
was adequately powered to assess the genotype–phenotype
associations and has highlighted a role for the dopamine-
related COMT gene, with the AA genotype involved in
mediating compulsive, stereotyped and challenging beha-
viours, as well as interest and pleasure. This highlights the
merit of investigating SNPs that are selected a priori on a
theoretical basis, in rare populations. Future studies should
strive to replicate this finding and explore the association
between other SNPs and behavioural phenotypes of FXS
and other neurodevelopmental disorders. In addition, the
present study failed to replicate previous findings reporting
an association between 5-HTTLPR genotypes and challen-
ging behaviour, possibly due to differences in severity of
challenging behaviours in the two samples. Future studies
should explore this further by examining additional risks for
increased severity of challenging behaviour. This study
identifies a role for additional neural and genetic risk factors
in understanding of the mechanisms contributing to clini-
cally significant phenotypic variability in neurodevelop-
mental disorders. This increased understanding has
implications for timely detection of clinically significant
behaviours, which can ultimately improve outcomes through
preventative interventions that are biologically informed.
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